Does GHK-Cu Need to Be Cycled? What the Studies Ran, What Nobody Has Tested, and the Copper Arithmetic

Our GHK-Cu articles already live here cover a lot of ground: what it is and how to buy it (buying guide), the research overview (longevity research), topical versus injectable data (topical vs. injection), why it stings (injection burning), GHK versus GHK-Cu versus AHK-Cu (copper peptides compared), hair (hair follicle research), loose skin after GLP-1 therapy (GLOW and loose skin), a 2026 mouse route preprint (route study), the GLOW stack (the GLOW stack), and the GLOW and KLOW buy pages. None answers the community's most common question: does GHK-Cu need to be "cycled," and what happens after stopping. This article lists what every study actually ran, states that no study has tested a cycle or discontinuation, lays out the copper arithmetic against oral and parenteral reference figures without calling anything safe, and checks the three convictions behind the question against the published record.

The question the community has already answered for itself

Our Reddit corpus, the 12 months to August 2026 (1 August 2025 to 6 August 2026), covers 148,085 posts from r/Peptides, r/Biohackers, r/PeptideDiscussion, r/Retatrutide, r/tirzepatidecompound, r/Semaglutide, r/BPC157 and r/sarmsourcetalk, pulled from a public archive: a community report, not a scientific sample. Of these, 2,933 posts name GHK-Cu, copper peptides, GLOW or KLOW in the title, and 295 of those 2,933 contain cycling, break, stopping, tolerance or copper-load language, concentrated in r/Peptides (145), r/Biohackers (78), r/PeptideDiscussion (52), r/Retatrutide (19) and r/tirzepatidecompound (1).

Themes overlap, so the counts do not sum to 295. Within the 295, 33 use the word "uglies," 22 mention zinc, 27 mention indefinite or continuous use, 14 ask what happens after stopping, and only 6 mention any blood work or copper marker. The monthly count rose from 28-31 per month in autumn 2025, peaked at 89 in January 2026, held at 70-74 through May, then fell to 27-28 in June and July.

The schedules that circulate are stated by posters as what they do or heard, with no cited source: "5 days on, 2 days off" (25 posts, the most frequent), "30 days on, 30 days off," "6 weeks on, 3 off," "6 on, 4 off," "8 on, 3 off," "8 on, 4 off," "10 on, 4 off," "2 weeks on, 2 off," run lengths of "4 weeks," "6-8 weeks," "8-12 weeks" and "10-12 weeks is ideal," and "just keep taking it." None of these is treated below as sensible, typical or conservative.

Representative thread titles (no links, no usernames): "Does GHK-Cu SC need to be cycled?" (fears benefits "go away" after stopping); "Messed Up with GHK-CU" (12 upvotes, 33 comments, a poster who had not known cycling was expected); "How long to see results from GHK-CU?" (28 upvotes, 48 comments, "what happens when you stop?"); "GHK-CU - Copper Uglies Something to Worry About" (28 comments, "can begin to break down collagen"); "Anyone got the copper uglies after starting GHK-CU?" (57 comments); "How much Zinc is recommended to prevent copper uglies" (29 comments); "Ghk-cu cycle was just okay"; "GHK-Cu before and after" (1,480 upvotes, 503 comments, a long-term hair self-report).

Three convictions drive the debate: that copper accumulates, that the effect wears off, and that the benefit reverses after stopping. Posters treat cycling as settled, cite no source, and disagree on nearly every number above. Section 10 returns to these convictions directly.

What every study actually ran

Human data on GHK-Cu is thin, and none of it addresses cycling. The only PubMed record for GHK-Cu carrying a randomized-controlled-trial publication type tested it topically in 13 completers after CO2 laser resurfacing: no significant between-group difference in erythema, wrinkle or skin-quality grading at 12 weeks, and the only positive result was patient-reported satisfaction (P = .04); the abstract reports no adverse-event or tolerability outcome at all (RCT; Miller et al. 2006, PMID 16847171). A separate randomized, evaluator-blinded, placebo-controlled trial of topical GHK-Cu gel on diabetic neuropathic plantar ulcers found median closure of 98.5% versus 60.8% (p < 0.05) and infection in 7% versus 34% of cases (p < 0.05); duration and number randomized were not retrievable (RCT; Mulder et al. 1994, PMID 17147644).

The only human data on injected copper tripeptide-1 is a six-active formulation (with VEGF, bFGF, IGF, KGF and thymosin beta-4) given intradermally into the scalp every 3 weeks for 8 sessions, about 24 weeks with no off-period, open-label in 1,000 patients: a significant reduction in hair fall on the pull test in 83% of patients, and a significant increase in total hair count at 1 year (P = 0.002) (open-label, single-arm, six actives combined; Kapoor and Shome 2018, PMID 29482481). A frequently cited photodamage study is often misattributed to GHK-Cu but tested manganese tripeptide-1 instead, with no control arm (Hussain and Goldberg 2007, PMID 18236243). Cosmetic-industry figures that also circulate (facial and eye cream trials, a thigh-skin comparison, a nano-lipid-carrier trial) are described only secondarily inside reviews and are not indexed in PubMed or MEDLINE.

Animal and in vitro work runs deeper, but no experiment varies a break or cycle as its subject. The table lists species, route, dose, duration, and whether anything was measured after stopping.

The two post-stop observations anywhere in this literature are the rat ACL study and the human scalp study above. In the ACL study, laxity was lower in both GHK-Cu groups at 6 weeks (p = 0.009), but by 12 weeks, about seven weeks after the last injection, laxity, load, gait and histology no longer differed, all grafts failed mid-substance, and the authors concluded "the beneficial effects could not last as treatment discontinued" (animal study; Fu et al. 2015, PMID 25731775). The scalp study imaged patients 2 months after a completed course but used no washout design, no control and six actives at once, so it cannot isolate a stopped GHK-Cu-only regimen (open-label; Kapoor and Shome, PMID 29482481). Hair-specific primary data barely exist: a 1991 conference note has no abstract and its sole affiliation is the company that developed the compound (Trachy et al. 1991, PMID 1809108); a 1993 paper describes "a copper binding peptide (PC1031)" enlarging follicles in fuzzy rats similarly to minoxidil, without identifying it as GHK-Cu and without dose or duration (Uno and Kurata 1993, PMID 8326148).

The cleanest single answer comes from a 2026 PRISMA systematic review of PubMed, Embase and Cochrane CENTRAL through March 2026, which included 20 studies (18 preclinical, 2 RCTs), notes adoption "despite a paucity of standardized clinical guidelines," and calls for trials "with standardized formulations, dosing regimens, and delivery methods" (systematic review; Mokhtar et al. 2026, PMID 42619529). A 2026 review of peptides in sports medicine names GHK-Cu among gray-market compounds, "rigorous human safety data are scarce" (review; Mendias and Awan 2026, PMID 41966639). Exactly one GHK-Cu record in PubMed carries a trial publication type, and a search combining GHK with cycling, intermittent dosing, washout or tachyphylaxis returns a single off-topic record; no study in any species compares continuous with intermittent dosing, tests a break interval, re-treats after a break, or measures tolerance.

Tolerance would need a receptor

The tolerance claim assumes something in the body adapts to repeated GHK-Cu exposure, the way a receptor adapts to a repeated agonist. No such receptor has been characterized: the field's own review offers only a figure captioned "Proposed cell receptor for GHK-Cu," not binding data (review; Pickart et al., Brain Sci 2017, PMID 28212278). The one documented receptor interaction involves the free peptide, not the copper complex, and is non-selective: in isolated rat hepatocytes, GHK stimulated phosphorylase a via IP3 and calcium, antagonized by losartan, with radioligand competition indicating interaction with angiotensin II AT1 receptors, though "other histidine-containing tripeptides were also capable of interacting with these receptors" (in vitro/animal study; García-Sáinz and Olivares-Reyes, Peptides 1995, PMID 8545239). Nothing on the copper complex specifically, and no desensitization measurement exists for GHK-Cu; a tolerance argument needs both a receptor and a desensitization curve, and this literature supplies neither.

A concentration ceiling in cell culture is sometimes read as tolerance, but it is different. Collagen synthesis in fibroblast culture peaked at 10^-9 M, independent of cell number, measuring synthesis alone (in vitro; Maquart et al., FEBS Lett 1988, PMID 3169264), and glycosaminoglycan synthesis was biphasic: "maximal stimulation at 10(-9) to 10(-8) M. At higher concentrations, the rate of synthesis returned progressively to that of control cultures" (in vitro; Wegrowski et al., Life Sci 1992, PMID 1522753). Both describe a single exposure at varying concentrations within one experiment, not repeated exposure over time; neither supports a cycling schedule.

The claim that GHK-Cu "modulates at least 4,000 human genes" is a back-calculation, not a count of measured genes: three GHK expression profiles across two of five Connectivity Map cell lines at 1 micromolar, MAS5-processed, with a 50%-change cutoff, no significance testing, no false-discovery-rate correction, and no biological replication (review, re-analysis of prior array data; Pickart et al. 2017, PMID 28212278). The 4,000 figure comes from 22,277 probe sets taken to represent 13,424 genes, of which 31.2% changed by at least 50%; the figure itself appears in the same authors' 2015 review (PMID 26236730), not in the 2017 paper that supplies the method, and not in their 2018 review. Independent bench replication does exist, using the free peptide: a Boston group linked 127 genes to emphysema severity across 64 lung-tissue samples from COPD smokers, then showed GHK at 0.1 nM and 10 nM for 48 hours restored collagen I contraction in COPD-derived fibroblasts (in vitro; Campbell et al., Genome Med 2012, PMID 22937864).

The copper arithmetic, and what it can and cannot be compared with

The free tripeptide GHK is PubChem CID 73587, MW 340.38 g/mol; the copper complex sold as GHK-Cu is CID 71587328, the monocation C14H23CuN6O4+, MW 402.92 g/mol, INCI name Copper Tripeptide-1 (a neutral variant, CID 165429100, is MW 401.91) (database identity; PubChem). Copper is 63.546 divided by 402.92, or 15.77% of the mass of GHK-Cu (15.81% for the neutral form): arithmetic on a database molecular weight, not a measured content, since what a given vial actually contains (free base, acetate or hydrate) is not established by any source used here. On that basis, 1 mg of GHK-Cu contains about 158 micrograms of copper, 10 mg about 1.58 mg, and a 50 mg vial about 7.89 mg.

Oral figures are not injection figures because absorption and excretion sit at two checkpoints unique to the gut. Fractional absorption of dietary copper falls as intake rises (over 50% below 1 mg/day, below 20% above 5 mg/day), and a clinical review puts oral absorption at "approximately 30%-40% of ingested" (Institute of Medicine 2001; de Man et al., JPEN 2025, PMID 39555865). The fall owes mainly to biliary excretion, "the main excretion mechanism," with urinary excretion minor at 11-60 micrograms per day (regulator document; EFSA Scientific Committee 2023, PMID 36694841). None of that first-pass regulation applies to copper that never passes through the gut, and no source used here measured what happens to copper delivered directly into tissue or plasma.

Healthy adults reached net-zero copper balance at 0.8-2.49 mg/day within 18-42 days across four studies, but at 6-8 mg/day, balance was not fully restored over 8, 3.5 and 21 weeks in three separate studies, with subjects still net-retaining copper. Assuming no further adaptation after 5 months, one study projected the copper body burden would double in 100-150 days at about 8 mg/day continuously, a projection EFSA flags as more uncertain than the observed data (regulator document; EFSA Scientific Committee 2023).

Parenteral nutrition is the closest documented analog to copper past the gut, and it points to a different variable than duration. In 28 long-term TPN adults versus 10 cholestatic controls, 89% had mildly elevated hepatic copper and 29% exceeded the Wilson-disease threshold; hepatic copper correlated with AST and bilirubin, but not with TPN duration (median 1.9 years, range 0.3-18.0) or serum copper, and the overload "occurs through chronic cholestasis... and is independent from the total duration of TPN" (retrospective study; Blaszyk et al. 2005, PMID 15758626). Failed biliary excretion is exactly the mechanism behind Wilson disease, from ATP7B mutations (review; Członkowska et al. 2018, PMID 30190489). Markers carry their own limits: ceruloplasmin carries over 95% of plasma copper and rises with inflammation; the low thresholds published in critically ill patients (serum copper below 12 micromol/L, ceruloplasmin below 20 mg/L) are deficiency thresholds, never toxicity ones (review; de Man et al. 2025, PMID 39555865), and one parenteral-nutrition review states there is "no well-established laboratory measurement of body copper status" at all (Shike 2009, PMID 19874945).

Does the copper stay in the complex?

Whether copper travels as an intact GHK-Cu molecule is a separate question, and the chemistry mostly says no. An isothermal-titration study reports a conditional dissociation constant for Cu(II)-GHK at pH 7.4 of 7.0 ± 1.0 x 10^-14 M, close to albumin fragment DAHK at 2.6 ± 0.4 x 10^-14 M (in vitro; Trapaidze et al. 2012, PMID 21898044). At equimolar albumin and peptide, about 42% of Cu(II) was bound to GHK, but at physiological concentrations only about 6% was associated with low-molecular-weight components like GHK (in vitro; Lau and Sarkar 1981, PMID 7340824). Two later papers describe ternary, not binary, species: GHK, Cu(II) and albumin form complexes with conditional constants of 2900 M-1 (His3) and about 1700 M-1 (His128/His510) (in vitro; Bossak-Ahmad et al. 2021, PMID 34730942), and GHK, Cu(II) and cis-urocanic acid form another (in vitro; Bossak-Ahmad et al. 2020, PMID 32867146). In plasma and skin the relevant chemistry is a set of ternary complexes, not a discrete GHK-Cu molecule circulating intact.

Two skin-permeation experiments used different preparations and must be read separately. Under an infinite dose of 0.68% aqueous copper as the tripeptide cuprate diacetate on excised human skin, 136.2 ± 17.5 micrograms of copper per cm2 permeated dermatomed human skin over 48 hours and 82 ± 8.1 micrograms per cm2 were retained there as a depot, measured as copper by ICP-MS, not as peptide (in vitro; Hostynek et al. 2010, PMID 20703511). A microneedle study found that over 9 hours, 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper crossed treated skin, while "almost no peptide or copper permeated through intact human skin" (in vitro; Li et al. 2015, PMID 25690343). The "almost no" result belongs to that study's intact-skin comparator alone, and says nothing about the dermatomed preparation Hostynek used. In the microneedle experiment roughly five times more copper than peptide crossed on a molar basis, which is consistent with the copper and the peptide separating under those conditions rather than proof that the complex never travels intact. One reading caution: the 136-microgram figure above is often restated elsewhere as "136 micrograms of GHK-Cu," but the original measurement was copper.

Pharmacokinetics agrees too. The only PubMed-indexed pharmacokinetic study gave GHK intravenously to rats: only rapid degradation to His-Lys is reported, with no half-life or clearance figure (animal study; Endo et al. 1997, PMID 9187381); the 2014 cosmetic safety assessment secondarily calls elimination "in minutes," GHK "unstable in human plasma" (cosmetic safety assessment; CIR Expert Panel 2014). A retro-inverso analog was built because it is about ten-fold more stable than the parent peptide in human plasma (in vitro; Dalpozzo et al. 1993, PMID 8349414), and synthetic analogs, not GHK itself, showed no significant degradation in human serum for at least 3 hours (in vitro; Conato et al. 2001, PMID 11325542). No human pharmacokinetic study of GHK or GHK-Cu exists by any route.

The copper uglies

The term "copper uglies" has no citable scientific origin: a PubMed search for it returns zero records, and the community threads that use it describe hearing it on short-video platforms, content not reviewed here. What the matrix-enzyme literature shows is more nuanced than "GHK-Cu breaks down collagen." In rat wound-chamber tissue, pro-MMP-2 rose to day 7, fell by day 18, then rose again at days 18 and 22; MMP-9 persisted to day 22, but interstitial collagenase activity was not altered (animal study; Siméon et al., J Invest Dermatol 1999, PMID 10383745). In cultured dermal fibroblasts, GHK-Cu increased MMP-2 secretion (reproduced by copper ions alone, not peptide alone) while simultaneously increasing the inhibitors TIMP-1 and TIMP-2 (in vitro; Siméon et al., Life Sci 2000, PMID 11045606). A widely repeated line that GHK-Cu "stimulates both synthesis and breakdown of collagen" traces to a primary source that measured synthesis alone, with no matched breakdown assay (in vitro; Maquart et al., FEBS Lett 1988, PMID 3169264).

Irritation testing points away from GHK-Cu specifically: in a keratinocyte model, GHK-Cu "was not cytotoxic and did not induce any significant change" in irritation biomarkers, while copper chloride and copper acetate at 58 and 580 micromolar significantly upregulated IL-1alpha, IL-8, HSPA1A and FOSL1; the authors concluded GHK-Cu "has a low potential of inducing skin irritation" (in vitro, 24-hour keratinocyte culture; Li et al., Sci Rep 2016, PMID 27892491). This is short-term in vitro data, not evidence about repeated human use. No human study reports a transient worsening phase after starting GHK-Cu, and the one RCT (the laser-resurfacing study above) reports no tolerability data at all, so it can neither confirm nor rule one out.

The cosmetic safety assessment concludes the ingredients it reviewed are safe "in the present practices of use and concentration," at typical concentrations "< 10 ppm," yet states verbatim that "studies designed to evaluate the repeated dose toxicity... were not found in the published literature," with reproductive, developmental and carcinogenicity data likewise not found (cosmetic safety assessment; Cosmetic Ingredient Review Expert Panel 2014). In its own data table, Copper Tripeptide-1 has no entries for irritation, sensitization, reproductive, developmental, genotoxicity, carcinogenicity or phototoxicity; the safe-as-used conclusion rests on read-across from other, non-copper peptides plus the low use concentration. The "< 10 ppm" figure itself originated as a market-practice comment by a cosmetic chemist, not a regulatory ceiling.

Zinc as a countermeasure

Community threads treat zinc as a standard way to head off the copper uglies, but every mechanism in the literature places the zinc effect at the intestinal lumen, not at the site of an injection. Zinc acetate is an approved maintenance therapy for Wilson disease, and it works by inducing metallothionein in intestinal cells, which blocks copper absorption both from dietary copper and from copper secreted endogenously in saliva, gastric juice and intestinal fluids; compliance is monitored with 24-hour urine copper and zinc, and gastric irritation occurs in about 10% of patients (clinical guidance; Brewer 2001, PMID 11585025). EFSA states the mechanism in one line: "Dietary zinc has a direct impact at the level of copper uptake as it is known to compete with copper transport and reduce gastrointestinal copper absorption" (regulator document; EFSA Scientific Committee 2023, PMID 36694841). No source used in this article discusses zinc alongside topical or injected copper peptides at all, so nothing here speaks to whether oral zinc has any effect on copper delivered by injection.

The risk of the countermeasure itself, however, is documented. A retrospective laboratory-database study found 23 instances of high zinc paired with low copper, 14 positively diagnosed and 7 of those (50%) previously undiagnosed before the study looked (retrospective clinical study; Duncan and Morrison, Br J Clin Pharmacol 2023, PMID 37070154). A pharmacovigilance analysis of large databases found copper deficiency reported in 100 of 2,646 (3.8%) adults on oral zinc, with an adjusted reporting odds ratio of 3.51 (95% CI 2.51-4.90) per 1 mg/kg/day of zinc, higher with chronic kidney disease, age 70 or over and female sex, a median onset of 137 days, and cytopenia in 85% to 93% of cases (pharmacovigilance study; Hiyama et al., Clin Nutr ESPEN 2026, PMID 42217623). The authors describe the 3.8% figure as a reporting rate rather than a true incidence.

Where the regulators stand, and why that is also an answer

The US route split is the whole regulatory story, and it has shifted more than once. On 29 September 2023, the FDA added "GHK-Cu (except for injectable routes of administration)" to Category 1 of its 503A bulk-drug-substances list, while adding "GHK-Cu for injectable routes of administration" to Category 2, "due to significant safety risks associated with its use in compounding" (regulator document; FDA, archived 29 September 2023). Its stated concern, verbatim: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations."

That position has since shifted. Per the FDA list updated 14 May 2026, non-injectable GHK-Cu was removed from Category 1 on 22 April 2026 after withdrawals, then a nominator clarified on 5 May 2026 it meant to withdraw only the injectable route and would retain the non-injectable nomination; non-injectable GHK-Cu returned to Category 1, and the FDA intends to consult the Pharmacy Compounding Advisory Committee before end of February 2027 (regulator document; FDA, updated 14 May 2026). Category 2 now holds six substances, none GHK-Cu; the injectable nomination sits instead in the FDA's "nominated but withdrawn" table. In plain terms: injectable GHK-Cu sat in Category 2 from September 2023 to the April 2026 withdrawal, and no equivalent injectable nomination is currently in place. This is US compounding law, not a safety verdict, and touches neither the EU position nor research-use-only status.

GHK-Cu was not part of the July 2026 advisory-committee meeting: the notice lists BPC-157, KPV, TB-500 and MOTS-c on 23 July and emideltide (DSIP), Semax and Epitalon on 24 July, GHK-Cu absent (regulator document; FDA/Federal Register, 91 FR 20465, 16 April 2026). A law-firm analysis states a second meeting, expected before end of February 2027, will address "LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF," rulemaking "typically" taking "12 to 24 months" (secondary legal analysis, not an FDA statement); a future agenda item is a recommendation process, not an approval.

In the EU, no medicinal product containing GHK-Cu is authorized centrally: the EMA's published export of centrally authorized products contains no occurrence of "tripeptide" or "GHK" (only copper (64Cu) chloride, a radiopharmaceutical precursor, appears under copper), though that export does not rule out a national authorization. GHK-Cu appears in cosmetics under INCI Copper Tripeptide-1, at concentrations customarily below 10 ppm (cosmetic safety assessment; CIR Expert Panel 2014); an INCI listing is not a medicinal registration, and "< 10 ppm" is a market-practice figure, not a legal limit. Separately, a copper-saline wound dressing was cleared through the FDA's 510(k) pathway in 1997 (K964468, ProCyte Corp., "Substantially Equivalent"), a device clearance, not a drug approval.

None of these documents address dosing schedules, cycling, washout or duration of use for GHK-Cu at all. That silence is itself the finding: the regulatory record tracks route and safety-data availability, not how long or how often a compound is used.

What our own certificates do and do not say

Read from the live product pages on 28 August 2026, GHK-Cu is listed here in 50 mg and 100 mg vials, category longevity; GLOW is GHK-Cu 50 mg plus BPC-157 10 mg plus TB-500 10 mg in a 70 mg vial, and KLOW adds KPV 10 mg in an 80 mg vial, both category regeneration (our own product documentation, dated 28 August 2026).

The GHK-Cu page carries four certificates: three manufacturer reports from Janoshik, dated 25 November 2025 (99.79% purity, 91.34 mg on a 100 mg label; 99.85%, 48.35 mg on a 50 mg label) and 27 January 2026 (99.45%, 114.58 mg on a 100 mg label), and one community-submitted report from Kovera Labs dated 27 June 2026 (99.87%, 56.42 mg on a 50 mg label). GLOW carries a manufacturer report from 30 October 2025 (GHK-Cu 46.38 mg, BPC-157 11.29 mg, TB-500 10.05 mg) and a report we commissioned ourselves at Liquilabs from 29 June 2026 (52.6/15.56/8.68 mg). KLOW carries a manufacturer report from 30 July 2026 (GHK-Cu 45.99 mg, BPC-157 10.84 mg, TB-500 10.95 mg, KPV 10.74 mg) (our own product documentation, current 28 August 2026).

These figures describe the specific vials tested, on the dates tested; they say nothing about what happens in a person and nothing about copper status. Paired only as arithmetic, never as exposure: the 45.99 mg KLOW lot above carries about 7.25 mg of copper by formula, on the same database molecular weight used throughout this article.

Against that, the 2014 cosmetic safety assessment notes "commercial GHK-Cu2+ (copper tripeptide-1) is approximately 95% pure, but often includes small amounts of mildly neurotoxic materials," removable by dissolving, centrifuging and lyophilizing (cosmetic safety assessment; Cosmetic Ingredient Review Expert Panel 2014). Our own reports above report purity between 99.45% and 99.87% for the GHK-Cu lots tested. Both figures describe what a certificate reports for a tested lot; neither says anything about exposure, response or copper status in a person.

Underneath all three convictions: what is untested

Section 1 named three convictions behind the community's cycling question: that copper accumulates, that the effect wears off, and that the benefit reverses once someone stops. Each conviction implies a specific measurement a study would have to make, and the table below states plainly whether that measurement exists anywhere in this literature.

This article recommends no schedule, because no study supports one. Whether continuous use is safer, riskier or no different from blocks with breaks is untested, and nothing in the pharmacology, the animal literature, the copper arithmetic or the regulatory record above changes that conclusion.

Where these products sit in our catalog

Frequently asked questions

Sources

1. National Library of Medicine, PubChem. Compound records for glycyl-L-histidyl-L-lysine (GHK, CID 73587), the copper complex sold as GHK-Cu (CID 71587328) and its neutral variant (CID 165429100). https://pubchem.ncbi.nlm.nih.gov/compound/73587, https://pubchem.ncbi.nlm.nih.gov/compound/71587328, https://pubchem.ncbi.nlm.nih.gov/compound/165429100
2. Campbell JD, McDonough JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID 22937864. https://pubmed.ncbi.nlm.nih.gov/22937864/
3. Endo T, Miyagi M, et al. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl. 1997;692(1):37-42. PMID 9187381. https://pubmed.ncbi.nlm.nih.gov/9187381/
4. Dalpozzo A, Kanai K, et al. H-Gly-His psi(NHCO)Lys-OH, partially modified retro-inverso analogue of the growth factor glycyl-L-histidyl-L-lysine with enhanced enzymatic stability. Int J Pept Protein Res. 1993;41(6):561-6. PMID 8349414. https://pubmed.ncbi.nlm.nih.gov/8349414/
5. Conato C, Gavioli R, et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta. 2001;1526(2):199-210. PMID 11325542. https://pubmed.ncbi.nlm.nih.gov/11325542/
6. Trapaidze A, Hureau C, et al. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID 21898044. https://pubmed.ncbi.nlm.nih.gov/21898044/
7. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PMID 7340824. https://pubmed.ncbi.nlm.nih.gov/7340824/
8. Bossak-Ahmad K, Bal W, et al. Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem. 2021;60(22):16927-16931. PMID 34730942. https://pubmed.ncbi.nlm.nih.gov/34730942/
9. Bossak-Ahmad K, Wisniewska MD, et al. Ternary Cu(II) Complex with GHK Peptide and Cis-Urocanic Acid as a Potential Physiologically Functional Copper Chelate. Int J Mol Sci. 2020;21(17). PMID 32867146. https://pubmed.ncbi.nlm.nih.gov/32867146/
10. Pickart L, Vasquez-Soltero JM, et al. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2). PMID 28212278. https://pubmed.ncbi.nlm.nih.gov/28212278/
11. Garcia-Sainz JA, Olivares-Reyes JA. Glycyl-histidyl-lysine interacts with the angiotensin II AT1 receptor. Peptides. 1995;16(7):1203-7. PMID 8545239. https://pubmed.ncbi.nlm.nih.gov/8545239/
12. Cosmetic Ingredient Review Expert Panel. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics. Washington, DC: Cosmetic Ingredient Review, 2014. https://www.cir-safety.org/sites/default/files/tripep062014final.pdf
13. Hostynek JJ, Dreher F, et al. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010;59(11):983-8. PMID 20703511. https://pubmed.ncbi.nlm.nih.gov/20703511/
14. Li H, Low YS, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015;32(8):2678-89. PMID 25690343. https://pubmed.ncbi.nlm.nih.gov/25690343/
15. Pickart L, Vasquez-Soltero JM, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
16. Deng M, Zhang Q, et al. Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle. 2023;14(3):1365-1380. PMID 36905132. https://pubmed.ncbi.nlm.nih.gov/36905132/
17. Miller TR, Wagner JD, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PMID 16847171. https://pubmed.ncbi.nlm.nih.gov/16847171/
18. Mulder GD, Patt LM, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PMID 17147644. https://pubmed.ncbi.nlm.nih.gov/17147644/
19. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth, safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20(6):369-379. PMID 29482481. https://pubmed.ncbi.nlm.nih.gov/29482481/
20. Hussain M, Goldberg DJ. Topical manganese peptide in the treatment of photodamaged skin. J Cosmet Laser Ther. 2007;9(4):232-6. PMID 18236243. https://pubmed.ncbi.nlm.nih.gov/18236243/
21. Cosmetic-industry facial cream, eye cream, thigh-skin and nano-lipid-carrier studies, described secondarily within review articles listed elsewhere in this Sources list; the original conference posters and the 1998 thigh-skin paper are not indexed in PubMed or MEDLINE.
22. Maquart FX, Bellon G, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. PMID 8227353. https://pubmed.ncbi.nlm.nih.gov/8227353/
23. Simeon A, Wegrowski Y, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-8. PMID 11121126. https://pubmed.ncbi.nlm.nih.gov/11121126/
24. Simeon A, Monier F, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999;112(6):957-64. PMID 10383745. https://pubmed.ncbi.nlm.nih.gov/10383745/
25. Simeon A, Emonard H, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. PMID 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/
26. Zhang Q, Yan L, et al. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. PMID 35936787. https://pubmed.ncbi.nlm.nih.gov/35936787/
27. Ma WH, Li M, et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020;241:117139. PMID 31809714. https://pubmed.ncbi.nlm.nih.gov/31809714/
28. Park JR, Lee H, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID 27517151. https://pubmed.ncbi.nlm.nih.gov/27517151/
29. Bian Y, Deng M, et al. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024;75:103237. PMID 38879894. https://pubmed.ncbi.nlm.nih.gov/38879894/
30. Fu SC, Cheuk YC, et al. Tripeptide-copper complex GHK-Cu(II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015;33(7):1024-33. PMID 25731775. https://pubmed.ncbi.nlm.nih.gov/25731775/
31. Parker NP, Ardeshirpour F, et al. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngol Head Neck Surg. 2013;149(3):384-9. PMID 23744835. https://pubmed.ncbi.nlm.nih.gov/23744835/
32. Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PMID 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/
33. Wegrowski Y, Maquart FX, et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-56. PMID 1522753. https://pubmed.ncbi.nlm.nih.gov/1522753/
34. Tucker M, Liao GY, et al. Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Aging Pathobiol Ther. 2024;6(3):102-108. PMID 40766919. https://pubmed.ncbi.nlm.nih.gov/40766919/
35. Mazzola J, Rosenfeld M, et al. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Res Sq. 2026 (preprint, not peer-reviewed). PMID 42245779. https://pubmed.ncbi.nlm.nih.gov/42245779/
36. Wen H, Zhao K, et al. The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways. Biogerontology. 2026;27(3). PMID 42084774. https://pubmed.ncbi.nlm.nih.gov/42084774/
37. Smakhtin MY, Sever'yanova LA, et al. Tripeptide Gly-His-Lys is a hepatotropic immunosuppressor. Bull Exp Biol Med. 2002;133(6):586-7. PMID 12447473. https://pubmed.ncbi.nlm.nih.gov/12447473/
38. Trachy RE, Fors TD, et al. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci. 1991;642:468-9. PMID 1809108. https://pubmed.ncbi.nlm.nih.gov/1809108/
39. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993;101(1 Suppl):143S-147S. PMID 8326148. https://pubmed.ncbi.nlm.nih.gov/8326148/
40. Mokhtar J, Mohamad B, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026. PMID 42619529. https://pubmed.ncbi.nlm.nih.gov/42619529/
41. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID 41966639. https://pubmed.ncbi.nlm.nih.gov/41966639/
42. EFSA Scientific Committee, More SJ, et al. Re-evaluation of the existing health-based guidance values for copper and exposure assessment from all sources. EFSA J. 2023;21(1):e07728. PMID 36694841. https://pubmed.ncbi.nlm.nih.gov/36694841/
43. Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press, 2001. https://doi.org/10.17226/10026
44. de Man AME, Stoppe C, et al. What do we know about micronutrients in critically ill patients? A narrative review. JPEN J Parenter Enteral Nutr. 2025;49(1):33-58. PMID 39555865. https://pubmed.ncbi.nlm.nih.gov/39555865/
45. Turnlund JR. Human whole-body copper metabolism. Am J Clin Nutr. 1998;67(5 Suppl):960S-964S. PMID 9587136. https://pubmed.ncbi.nlm.nih.gov/9587136/
46. Shike M. Copper in parenteral nutrition. Gastroenterology. 2009;137(5 Suppl):S13-7. PMID 19874945. https://pubmed.ncbi.nlm.nih.gov/19874945/
47. Vanek VW, Borum P, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-91. PMID 22730042. https://pubmed.ncbi.nlm.nih.gov/22730042/
48. Blaszyk H, Wild PJ, et al. Hepatic copper in patients receiving long-term total parenteral nutrition. J Clin Gastroenterol. 2005;39(4):318-20. PMID 15758626. https://pubmed.ncbi.nlm.nih.gov/15758626/
49. Czlonkowska A, Litwin T, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. PMID 30190489. https://pubmed.ncbi.nlm.nih.gov/30190489/
50. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opin Pharmacother. 2001;2(9):1473-7. PMID 11585025. https://pubmed.ncbi.nlm.nih.gov/11585025/
51. Duncan A, Morrison I, et al. Iatrogenic copper deficiency: Risks and cautions with zinc prescribing. Br J Clin Pharmacol. 2023;89(9):2825-2829. PMID 37070154. https://pubmed.ncbi.nlm.nih.gov/37070154/
52. Hiyama Y, Yamada T, et al. Characterizing clinical patterns and associated factors of zinc-induced copper deficiency: Insights from large-scale pharmacovigilance databases. Clin Nutr ESPEN. 2026;74:103368. PMID 42217623. https://pubmed.ncbi.nlm.nih.gov/42217623/
53. Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology. 2003;189(1-2):147-63. PMID 12821289. https://pubmed.ncbi.nlm.nih.gov/12821289/
54. Miller DM, DeSilva D, et al. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79-84. PMID 2244543. https://pubmed.ncbi.nlm.nih.gov/2244543/
55. Thomas CE. The influence of medium components on Cu(2+)-dependent oxidation of low-density lipoproteins and its sensitivity to superoxide dismutase. Biochim Biophys Acta. 1992;1128(1):50-7. PMID 1390878. https://pubmed.ncbi.nlm.nih.gov/1390878/
56. Min JH, Sarlus H, et al. Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Metallomics. 2024;16(5). PMID 38599632. https://pubmed.ncbi.nlm.nih.gov/38599632/
57. Li H, Toh PZ, et al. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep. 2016;6:37664. PMID 27892491. https://pubmed.ncbi.nlm.nih.gov/27892491/
58. US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, version archived 29 September 2023 (Category 1 non-injectable GHK-Cu nomination; Category 2 injectable GHK-Cu addition). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
59. US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, including the stated safety concern for injectable GHK-Cu and the "bulk drug substances nominated but withdrawn" table, content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
60. US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, version updated 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
61. US Food and Drug Administration / Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments, Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. 91 FR 20465, 16 April 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
62. Law-firm regulatory analysis of the FDA's Section 503A bulk drug substances nomination process, cited for the expected pre-February-2027 Pharmacy Compounding Advisory Committee agenda (LL-37, GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF) and the typical 12-to-24-month rulemaking timeline. Secondary legal commentary, not an FDA statement.
63. European Medicines Agency, export of centrally authorized medicinal products, checked for "tripeptide" and "GHK" occurrences; no match for GHK-Cu, the only copper-related entry being the radiopharmaceutical precursor copper (64Cu) chloride. https://www.ema.europa.eu/en/medicines
64. PeptidesDirect product pages and lab-report certificates for GHK-Cu, GLOW and KLOW, read 28 August 2026. /coa

Research use only. GHK-Cu, GLOW and KLOW are supplied for laboratory research, not for human or animal administration, and not as medicines. Nothing in this article is dosing, cycling, break, tapering or reconstitution guidance, no schedule is recommended, and nothing here claims that any product works or that our own certificate figures describe anything beyond the specific vials tested.